March 24, 2021 8:09am

My concerns surround the cell and gene therapy sector, concerning when the sector runs-out of committed buyers?

Pre-open indications:  4 BUY and 3 SELLs; Mentioned: BLFS, BSTG, EDIT, IONS, BCLI, SLDB, EDIT, SGMO

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

Sector intel, ideas and opinions; Insight from a volatile climate; RMi defining the mitigating factors of share pricing! 


Dow futures are UP +0.27% (+86 points), S&P futures are UP +0.30% (+12 points) and NASDAQ futures are UP +0.67% (+88 points)


U.S. stocks are set to rebound on Wednesday

European markets were lower amid renewed concerns over the global economic recovery outlook, given a surge of Covid infections in Europe and renewed lockdowns,

Asia-Pacific markets were also lower as concerns over the world’s recovery from the pandemic weighed on investor sentiment.



RENEWED concerns affecting markets: many regions globally are seeing an increase in new Covid-19 cases as highly contagious variants continue to spread. In Europe, authorities continue battle a third Covid wave.

This current sector scenario is more than the rotation to economic recovery stocks; one thing we haven’t experienced any REAL news in the sector, shrinking equity pricing by electronic trading (a crash in IONS’ P3 trial with partner Roche, an all-stock merger to cover a Q4 loss at BLFS …

  • Even further offset, the small-cap benchmark Russell 2000 fell 3.58%, for its worst day since June 2020 to which the sector belongs.

We are under-achieving and loosing in a booming market, we need the EYES back on the REAL drug development …


Tuesday’s evening’s recap: “when you acclaim the gains, be ready for the pain; back to my mantra, “How many times when we see highs, we say BYE not buy” …

  • The Nasdaq closed DOWN – 149.84 points (-1.12%);
  • the IBB closed down -3.93% and XBI closed down -5.83%;
  • Sector volume had LOW with 1 of the 3-upside having higher than the 3-month average volume with the volume of 12 of 31-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +1.42 points or +7.52% at 20.30;
  • Tuesday’s percentage (%) of the 3-upside were +1.70% (MDXG) to +8.48% (BLFS) while the 31-downside ranges from -1.93% (MESO) to -21.66% (IONS);

March: 7 positive, 9 negative and 1 neutral closes

February: 9 positive, 10 negative closes and 1 holiday

January: 10 positive, 9 negative closes and 1 holiday


Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell: Questions continue …

Biostage (BSTG) closed up +$0.04 to $1.54 with 1,001 shares traded after Monday’s +$0.05 to $1.50 with 2001 shares traded (“pumping and promoting” again?), Friday’s +$0.13 to $1.45 with 605 shares traded, Thursday’s +$0.02 to $1.32 with 375 shares traded and last Wednesday’s flat at $1.30 with 36 shares traded.

Question#1: WHEN are the 10-K and 10-Q filings to be filed versus due?

Question#2: WHY is this board of directors in the position of “seeing no problem, hearing no problem, and communicating no problem?

Question#3: RSM US LLP, will their AUDIT “OPINION” be “CRAYONED” about the MANY operational issues, lack of strategy and focus especially when they “seem” to be “pumping and promoting “the daily share price with stimulated volume”?

MINORITY PUBLIC shareholders are waiting, watching and weighting responses to MAINTAIN their RIGHTS.


SELL from BUY:

BioLife Solutions (BLFS) closed up +$3.41 to $41.98 after Monday’s -$0.19 to $38.57 with a negative -$0.48 or -1.14% after the news of Q4 earnings’ loss and an all-stock merger with Stirling Ultracold; a “whole lot” of shares hitting float and outstanding in an all-stock merger.

Sangamo Therapeutics (SGMO) closed down -$1.00 to $12.59 after Monday’s $13.59 and Friday’s $13.23 with a negative -$0.15 or -1.19% pre-market indication

BUY after Decline:

Editas Medicine (EDIT) closed down -$2.40 to $46.08 after Monday’s +$3.48 to $48.48, Friday’s $45.00, Thursday’s $43.25 and last Wednesday’s $46.57 with a positive +$0.62 or +1.35% pre-market indication.

Ionis Pharmaceuticals (IONS) closed down -$12.05 to $43.59 after P3 drug candidate crash that was partnered with Roche with a positive +$0.21 or +$0.48% pre-market indication.


BUY as offering closes:

Solid Biosciences (SLDB) closed down -$0.15 to $5.51 after Monday’s $5.66 and Friday’s $5.82 with a positive +$0.34 or +6.17% pre-market indication.


BUY with News:

Brainstorm Cell Therapeutics (BCLI) closed down -$0.20 to $3.92 with a positive +$0.90 or +22.96% pre-market indication on news of topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). The study achieved the primary endpoint of safety and improvements were observed in secondary endpoints spanning neurologic function, cognition, and biomarkers.


The BOTTOM LINE: When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

Another one of my ‘cisms: “Momentum is fragmented, volatility exceeds volume and we shouldn’t base our buying positions in this climate on hope!”

I STILL am a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim … ANY new highs … if one can!”

Many talk of horizons; “as I have said last week, my horizon is usually a Friday’s close …”


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.